eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
2/2024
vol. 26
 
Share:
Send email
Share:
Research paper

An analysis of probiotic use for treatment of Clostridioides difficile infections in patients hospitalized at the University Clinical Hospital in Wroclaw, Poland, 2016–2018

Mateusz Piotr Baran
1
,
Jarosław Drobnik
2
,
Mária Belovičová
3, 4, 5
,
Štefánia Moricová
6
,
Piotr Pobrotyn
7

  1. Individual Specialist Medical Practice Mateusz Baran, Wroclaw, Poland
  2. Department of Family Medicine, Wroclaw Medical University, Wroclaw, Poland
  3. Faculty of Public Health Studies, Department of Preventive and Clinical Medicine, Slovak Medical University, Bratislava, Slovakia
  4. Internal Clinic for Liver Disease Diagnosis and Treatment, Remedium s.r.o., Bardejov Spa, Slovakia
  5. Slovak Society of Practical Obesitology (SSPO), Bardejov, Slovakia
  6. Faculty of Public Health Studies SZU, Institute of Occupational Health Service, Bratislava, Slovakia
  7. Remedial Specialistic Clinic “Pulsantis Sp. z o.o.”, Wroclaw, Poland
Family Medicine & Primary Care Review 2024; 26(2): 155–160
DOI: https://doi.org/10.5114/fmpcr.2024.139023
Online publish date: 2024/06/17
Article file
- 02 FM&PCR 2 24 - O - Baran - 1512 - An analysis.pdf  [0.47 MB]
Get citation
 
PlumX metrics:
 
1. Mirecka A. Zakażenia Clostridium difficile – nadal aktualny problem leczniczy i epidemiologiczny. Przegl Epidemiol 2017; 71(2): 155–164 (in Polish).
2. Sucher A, Biehle L, Smith A, et al. Updated Clinical Practice Guidelines for Clostridioides difficile Infection in Adults. US Pharm 2021; 46(12): HS10–HS16.
3. Viscidi R, Willey S, Bartlett JG, et al. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterol 1981; 81: 5–9.
4. Tullus K, Aronsson B, Marcus S, et al. Intestinal colonization with Clostridium difficile in infants up to 18 months of age. Eur J Clin Microbiol Infect Dis 1989; 8: 390–393.
5. McFarland L, Mulligan M, Kwok R, et al. Nosocomial acquisition of Clostridium difficile infection. N Eng J Med 1989; 320(4): 204–210.
6. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and news strategies Lancet Infect Dis 2005; 5: 549–557.
7. Gayane M, Hryniewicz W, Ozorowski T, et al. Zakażenia Clostridioides (Clostridium) difficile: epidemiologia, diagnostyka, terapia, profilaktyka. Warszawa: Narodowy Instytut Leków; 2018 (in Polish).
8. Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 2021; 73(5): 1029–1044.
9. Prehn J, van, Reigadas E, Vogelzang EH, et al. Guideline Committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021; 27(Suppl. 2): 1–21.
10. Kelly CR, Fischer M, Allegretti, JR, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol 2021; 116(6): 1124–1147.
11. Wnęk D. Probiotyki, prebiotyki i synbiotyki [cited 8.10.2023]. Available from URL: https://www.mp.pl/pacjent/dieta/zasady/ 142829,probiotyki-prebiotyki-i-synbiotyki/ (in Polish).
12. Castagliuolo I, LaMont JT, Nikulasson ST, et al. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 1996; 64: 5225–5232.
13. Kaur S, Vaishnavi C, Prasad KK, et al. Effect of Lactobacillus acidophilus & epidermal growth factor on experimentally induced Clostridium difficile infection. Indian J Med Res 2011; 133: 434–441.
14. Mehlich A, Górska S, Gamian A, et al. Wybrane aspekty zakażeń Clostridium dificille. Post Hig Med Dosw 2015; 69: 598–611 (in Polish).
15. Lee JS, Chung MJ, Seo JG. In vitro evaluation of antimicrobial activity of lactic acid bacteria against Clostridium difficile. Toxicol Res 2013; 29: 99–106.
16. Enterol. Indeks leków medycyny praktycznej [cited 8.10.2023]. Available from URL: https://indeks.mp.pl/leki/desc.php?id=1131/ (in Polish).
17. LacidoEnter. Indeks leków medycyny praktycznej [cited 8.10.2023]. Available from URL: https://indeks.mp.pl/leki/desc.php?id=1131/ (in Polish).
18. Lacidofil. Indeks leków medycyny praktycznej [cited 8.10.2023]. Available from URL: https://indeks.mp.pl/leki/desc.php?id=5084/ (in Polish).
19. Lakcid, Lakcid forte. Indeks leków medycyny praktycznej [cited 8.10.2023]. Available from URL: https://indeks.mp.pl/leki/desc.php?id=5421/ (in Polish).
20. Sanprobi IBS. Indeks leków medycyny praktycznej [cited 8.10.2023]. Available from URL: https://indeks.mp.pl/leki/subst.html?id=496&phrase=Sanprobi+IBS (in Polish).
21. Trilac Plus. Indeks leków medycyny praktycznej [cited 8.10.2023]. Available from URL: https://indeks.mp.pl/leki/desc.php?id=13270/ (in Polish).
22. Osłonka Gasro. Indeks leków medycyny praktycznej [cited 8.10.2023]. Available from URL: https://indeks.mp.pl/leki/desc.php?id=14915/ (in Polish).
23. Nood E, van, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407–415 (in Polish).
24. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridum difficile infection. Clin Infect Dis 2011; 53: 994–1002.
25. Wombwell E, Patterson ME, Bransteitter B, et al. The effect of Saccharomyces boulardii primary prevention on risk of Hospital Onset Clostridioides difficile infection in hospitalized patients administered antibiotics frequently associated with Clostridioides difficile infection. Clin Infect Dis 2021; 73(9): e2512–e2518.
26. Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013; 382: 1249–1257.
27. Johnston B, Ma S, Goldenberg J, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 878–888.
28. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008; 23(1): CD004611.
29. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271(24): 1913–1918.
30. Thygesen JB, Glerup H, Tarp B. Saccharomyces boulardii fungemia caused by treatment with a probioticum. BMJ Case Reports 2012: bcr0620114412.
Copyright: © 2024 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.